

F1

(i) an amino acid sequence which has an equivalent specificity or binding affinity to human MHC molecules as the amino acid sequence shown in (a), (b), (c), (d), (e), (f), (g) or (h);

wherein said peptide or peptide derivative has a length of up to 25 amino acids

REMARKS


The Office Action of July 27, 2001 and the Advisory Action of November 16, 2001 have been noted and carefully reviewed, and the foregoing amended claim is a complete response thereto.

Claims 1-3 and 5-54 are all the pending claims for this application. By this Amendment, claim 1 has been amended to delete "and/or" phraseology and the term "or" has been substituted therefor. This amendment to claim does not raise an issue of new matter, but is fully supported by the original specification.

In view of the complete response filed in the Amendment of September 27, 2001 along with this Second Amendment, Applicants respectfully submit that the claims are now in condition for allowance, and request that the Examiner consider and enter the amended claims and that the application now pass to issuance.

In the event this paper is not timely filed, Applicants hereby petition for an appropriate extension of time. The fee for this extension may be charged to our Deposit Account No. 01-2300, along with any other additional fees which may be required with respect to this paper.

Respectfully submitted,
Arent Fox Kintner Plotkin & Kahn, PLLC

A handwritten signature in black ink, appearing to read "Lynn A. Bristol". The signature is fluid and cursive, with a large loop at the end.

Lynn A. Bristol
Registration No. 48,898

1050 Connecticut Avenue, N.W.
Suite 400
Washington, D.C. 20036-5339
Tel: (202) 857-6000

Atty. Docket No. 100564-07029

LAB/ccd

U.S. Application No. 08/981,824

MARKED-UP COPY OF CLAIM 1

1. (Six times Amended) Peptide or peptide derivative comprising:

(a) the amino acid sequence (SEQ ID NO:1)

D-V-N-Y-A-F-L-H-A-T-D-L-L-P-A-C-D-G-E-R,

(b) the amino acid sequence (SEQ ID NO:2)

S-N-M-Y-A-M-M-I-A-R-F-K-M-F-P-E-V-K-E-K,

(c) the amino acid sequence (SEQ ID NO:3),

N-W-E-L-A-D-Q-P-Q-N-L-E-E-I-L-M-H-C-Q-T,

(d) the amino acid sequence (SEQ ID NO:4)

T-L-K-Y-A-I-K-T-G-H-P-R-Y-F-N-Q-L-S-T-G,

(e) the amino acid sequence (SEQ ID NO:5)

P-R-Y-F-N-Q-L-S-T-G-L-D-M-V-G-L-A-A-D-W,

(f) the amino acid sequence (SEQ ID NO:6)

T-Y-E-I-A-P-V-F-V-L-L-E-Y-V-T-L-K-K-M-R,

(g) the amino acid sequence (SEQ ID NO:7)

F-F-R-M-V-I-S-N-P-A-A-T-H-Q-D-I-D-F-L-I , wherein the peptide or

peptide derivative of SEQ ID NO. 7 comprises a C-terminal isoleucine residue,

(h) a partial region of the amino acid sequence shown in (a), (b), (c),

(d), (e), (f) [and/or] or (g) with a length of at least 6 amino acids, [and/or] or

(i) an amino acid sequence which has an equivalent specificity [and/or] or

binding affinity to human MHC molecules as the amino acid sequence

shown in (a), (b), (c), (d), (e), (f), (g) [or/and] or (h);

wherein said peptide or peptide derivative has a length of up to 25 amino acid